Evaluation of Anti-Diabetic Activity of Galinosa parviflora in  Diabetic Rats

Ganesh G. Dhakad; Deepak S. Mohale; A.V. Chandewar

doi:10.52711/2321-5836.2024.00025

Research Journal of Pharmacology and Pharmacodynamics

ISSN

2321-5836 (Online)
0975-4407 (Print)

Submit Article

Evaluation of Anti-Diabetic Activity of Galinosa parviflora in Diabetic Rats

Author(s): Ganesh G. Dhakad, Deepak S. Mohale, A.V. Chandewar

Email(s): ganeshdhakad552@gmail.com

DOI: 10.52711/2321-5836.2024.00025

Address: Ganesh G. Dhakad, Deepak S. Mohale, A.V. Chandewar
Pataldhamal Wadhwani College of Pharmacy, Yavatmal.
*Corresponding Author

Published In: Volume - 16, Issue - 3, Year - 2024

View HTML

View PDF

ABSTRACT:
Galinosa parviflora commonly known as Potato weed widely used in traditional system of medicine for the treatment of diabetes mellitus In the present study, Methanol extract of Galinosa parviflora (MEGP) leaves were subjected to phytochemical investigation and evaluated for antidiabetic activity in STZ induced diabetic rats. MEGP (100, 200 mg/kg) and Glibenclamide (5mg/kg) were administered orally in STZ (60mg/kg, i.p.) induced diabetic rats. In acute oral toxicity (OECD Guide line 423) study, administration of MEGP no mortality upto 1000 mg/kg was observed. OGTT, Fasting blood glucose level, body weight, plasma insulin, were evaluated in normal and diabetic rats. preliminary phytochemical investigation revealed the presence of alkaloids, flavonoids, glycosides, tannins as the major constituents in the methanol extract of Galinosa parviflora. These results suggest that MEGP (200mg/kg) showed antihyperglycemic activity in STZ induced diabetic rats.

Keywords:

Cite this article:
Ganesh G. Dhakad, Deepak S. Mohale, A.V. Chandewar. Evaluation of Anti-Diabetic Activity of Galinosa parviflora in Diabetic Rats. Research Journal of Pharmacology and Pharmacodynamics.2024;16(3):143-2. doi: 10.52711/2321-5836.2024.00025

Cite(Electronic):
Ganesh G. Dhakad, Deepak S. Mohale, A.V. Chandewar. Evaluation of Anti-Diabetic Activity of Galinosa parviflora in Diabetic Rats. Research Journal of Pharmacology and Pharmacodynamics.2024;16(3):143-2. doi: 10.52711/2321-5836.2024.00025 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-3-2

REFERENCES:
1.    Blair M. Diabetes mellitus review. Urologic Nursing. 2016 Jan 1; 36(1).
2.    Eisenbarth GS. Type I diabetes mellitus. New England Journal of Medicine. 1986 May 22; 314(21):1360-8.
3.    Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handbook of Clinical Neurology. 2014 Jan 1; 126: 211-22.
4.    Nathan DM. Long-term complications of diabetes mellitus. New England journal of medicine. 1993 Jun 10; 328(23): 1676-85.
5.    Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nature reviews Disease Primers. 2017 Mar 30; 3(1): 1-7.
6.    Goyal, Rajeev, and Ishwarlal Jialal. "Diabetes Mellitus Type 2." (2018).
7.    Buchanan TA, Xiang AH. Gestational diabetes mellitus. The Journal of Clinical Investigation. 2005 Mar 1; 115(3): 485-91.
8.    Todd JA. Etiology of type 1 diabetes. Immunity. 2010 Apr 23; 32(4): 457-67.
9.    Taylor R. Type 2 diabetes: Etiology and Reversibility. Diabetes Care. 2013 Apr 1; 36(4): 1047-55.
10.    Buchanan TA, Xiang AH. Gestational diabetes mellitus. The Journal of Clinical Investigation. 2005 Mar 1; 115(3): 485-91.
11.    Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. International journal of molecular sciences. 2018 Oct 26; 19(11): 3342.
12.    Visweswara Rao P, Hua Gan S. Recent advances in nanotechnology-based diagnosis and treatments of diabetes. Current Drug Metabolism. 2015 Jun 1; 16(5): 371-5.
13.    Guthrie RA, Guthrie DW. Pathophysiology of diabetes mellitus. Critical Care Nursing Quarterly. 2004 Apr 1; 27(2): 113-25.
14.    Modi P. Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. Current Drug Discovery Technologies. 2007 Jun 1; 4(1): 39-47.
15.    Al-Rowais NA. Herbal medicine in the treatment of diabetes mellitus. Saudi Medical Journal. 2002 Nov 1; 23(11): 1327-31.
16.    Ali S, Zameer S, Yaqoob M. Ethnobotanical, phytochemical and pharmacological properties of Tricholepis glaberrima (Asteraceae): A review. Tropical Journal of Pharmaceutical Research. 2017 Dec 1; 16(12).
17.    Ripanda A, Luanda A, Sule KS, Mtabazi GS, Makangara JJ. Tricholepis glaberrima (Cav.): A comprehensive review on ethnomedicinal, phytochemical and pharmacological studies. Heliyon. 2023 Feb 8.
18.    Damalas CA. Distribution, biology, and agricultural importance of Tricholepis glaberrima (Asteraceae). Weed Biology and Management. 2008 Sep; 8(3): 147-53.
19.    Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocrine Reviews. 1987 May 1; 8(2): 132-41.
20.    Golbidi S, Alireza Ebadi S, Laher I. Antioxidants in the treatment of diabetes. Current diabetes reviews. 2011 Mar 1; 7(2): 106-25.
21.    Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biological Psychiatry. 2003 Aug 1; 54(3): 317-29.
22.    Al-Ishaq, Raghad Khalid, Mariam Abotaleb, Peter Kubatka, Karol Kajo, and Dietrich Büsselberg. Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels. Biomolecules. 2019; 9(9): 430.
23.    De Cauwer B., et al. Effects of soil and crop management practices and pedo- hydrological conditions on the seedbank size of Galinsoga spp . in organic vegetable fields. December. 2021: 55–67. doi: 10.1111/wre.12457. 2019
24.    Studzinska-Sroka E., et al. Anti-inflammatory activity and phytochemical profile of Galinsoga parviflora cav. Mol. 2018; 23(9): 2133, Aug. doi: 10.3390/MOLECULES23092133. 2018, Vol. 23, Page 2133
25.    amesar S., Baijnath H., Govender T., Mackraj I. Angiotensin I-converting enzyme inhibitor activity of nutritive plants in Kwa Zulu-Natal. J. Med. Food. 2008; 11(2): 331–336. doi: 10.1089/jmf.2007.569. Jun.
26.    Ripanda A, Luanda A, Sule KS, Mtabazi GS, Makangara JJ. Galinsoga parviflora (Cav.): A comprehensive review on ethnomedicinal, phytochemical and pharmacological studies. Heliyon. 2023 Feb 1; 9(2).
27.    Shetty AK, Kumar GS, Sambaiah K, Salimath PV. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Foods for Human Nutrition. 2005; 60(3): 109–112.
28.    Sunmonu TO, Afolayan AJ. Evaluation of antidiabetic activity and associated toxicity of Artemisia afra aqueous extract in wistar rats. Evidence-Based Complementary and Alternative Medicine. 2013 Jan 1; 2013.
29.    Silbernagel E, Spreitzer H, Buchbauer G. Non-volatile constituents of Artemisia afra. Monatshefte für Chemie Chemical Monthly. 1990; 121(5): 433–436.
30.    Al-Shamaony L, Al-Khazraji SM, Twaij HAA. Hypoglycaemic effect of Artemisia herba alba. II. Effect of a valuable extract on some blood parameters in diabetic animals. Journal of Ethnopharmacology. 1994; 43(3): 167–171.
31.    Brewer HB., Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. American Journal of Cardiology. 1999; 83(9): 3F–12F.
32.    Porter JR, Barrett TG. Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure. Journal of Medical Genetics 2005; 42(12): 893-902.
33.    Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nature Medicine. 2011; 17(4): 448-53.
34.    Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care. 2010; 33(10):